FDA rejects lung cancer drug ivonescimab
The FDA has rejected ivonescimab, a lung cancer drug from Summit Therapeutics and Chinese drugmaker Akeso. It slowed the cancer in a global trial. But regulators said it did not show that patients lived longer. Some had hoped it could rival Keytruda.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.